Cancer Therapy Advisor14h
Denosumab Biosimilars Stoboclo and Osenvelt Get FDA Approval
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Managed Healthcare Executive20h
Novo Nordisk Lowers Wegovy Price for Cash-Paying Patients
NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.
Managed Healthcare Executive20h
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...